Crossmark

Sequential therapeutic approach for the management of osteoporosis in people with chronic kidney disease

Published Online: 2026-06-16

Published Print: 2026-08

Authors

Evenepoel, Pieter https://orcid.org/0000-0002-0797-4321
Jørgensen, Hanne Skou https://orcid.org/0000-0002-0881-2615
Nickolas, Thomas L.
License Information

Text and Data Mining valid from 2026-06-16

Version of Record valid from 2026-06-16
More Information

Article History

First Online: 16 June 2026

Ethics

Competing interests: H.S.J. declares financial support by Abiogen Pharma and UCB. T.L.N. declares financial support by Amgen, Pathalys, MICOT Pharma, Pharmacosmos, Abiogen Pharma and Intas Pharma. P.E. declares no competing interests.

Document is current